Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL2L1 antisense RNA 1 (BCL2L1-AS1)
- Target
- BCL2L1-AS1
- Molecular classification
- Other, Long non-coding RNA, lncRNA
01
Overview
BCL2L1 antisense RNA 1 is a long non-coding RNA transcribed antisense from the BCL2L1 locus on chromosome 20q11.21[4][10]. As a lncRNA, BCL2L1-AS1 is believed to participate in the regulation of its sense gene, BCL2L1, which encodes the anti-apoptotic protein Bcl-xL. The methylation status of the BCL2L1-AS1 genomic region has been identified as a predictive biomarker for the response to MCL1 inhibitors in pediatric high-grade gliomas, indicating a potential regulatory and prognostic role in cancer therapy[5]. To date, BCL2L1-AS1 is not itself a direct therapeutic target of drugs, but its molecular influence on apoptosis and drug resistance pathways is under investigation.
- Other names
- ABALON
02
Mechanism of action
Not directly applicable; as a lncRNA, potential mechanisms include regulation of sense gene (BCL2L1) expression via epigenetic modification or RNA interference
03
Biological functions
Potential regulator of BCL2L1 gene expressionModulate expression of the sense gene epigeneticallyModulate expression of the sense gene transcriptionally
04
Disease associations
CancerPediatric high-grade gliomas
05
Safety considerations
No specific safety concerns known for BCL2L1-AS1 itselfPotential off-target effects if targeted lncRNA therapies or antisense oligonucleotides are developedPotential immune responses if targeted lncRNA therapies or antisense oligonucleotides are developed
06
Biomarkers
Methylation status in the BCL2L1-AS1 region (clustered CpG sites) acts as a biomarker for predicting response to MCL1 inhibitors in pediatric gliomas
Beyond the preview
Go deeper on BCL2L1 antisense RNA 1 (BCL2L1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCL2L1 antisense RNA 1 (BCL2L1-AS1).